Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 4Carcinoma, Renal Cell 3Thyroid Cancer, Papillary 2Adenocarcinoma, Follicular 2Thyroid cancer, medullary 1Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Thrombocytosis 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 3Carboplatin 3Nivolumab 2Injections 2Docetaxel 2Cisplatin 2BMS-753493 2zimberelimab 1urelumab 1tislelizumab 1tesetaxel 1spartalizumab 1olaparib 1liposomal doxorubicin 1linifanib 1lenvatinib 1ixabepilone 1durvalumab 1avelumab 1avdoralimab 1adavosertib 1TAS-119 1Rifampin 1N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1Maximum Tolerated Dose 1Linoleic Acids, Conjugated 1Lapatinib 1Itraconazole 1Irinotecan 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Tumors × lenvatinib × Clear all
NCT01433991 2021-06-08

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Eisai Inc.

Phase 1/2 Terminated
30 enrolled 42 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡